NEWS

In this issue, findings from the RJBC 1501 trial in early triple-negative breast cancer show that adding adjuvant carboplatin to an anthracycline-taxane chemotherapy backbone improves overall survival in early triple-negative breast cancer.

We have attached the PDF, and you can also view the issue online.

Some of the other highlights include:

• Real-world post-progression outcomes after CDK4/6 inhibitors
• Impact on women of population-based breast density notification in Australia
• Interruption of tamoxifen for pregnancy 

We trust you will find these articles interesting and clinically valuable and look forward to bringing you more exciting updates throughout 2026.